Tirzepatide drugs: what Mounjaro is, how it works, and who it's for

What makes tirzepatide different from other weight-loss drugs?

Most GLP-1 medicines work on a single receptor. Tirzepatide works on two: the GLP-1 receptor and the GIP receptor. Both are involved in how the body regulates appetite, blood sugar, and how quickly food moves through the stomach. Activating both pathways at once appears to produce stronger appetite suppression and greater calorie reduction than single-agonist medicines in head-to-head comparisons.

That dual mechanism is why tirzepatide sits in its own category. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4mg over 72 weeks. On average, participants taking tirzepatide lost more weight. NICE referenced this evidence when recommending tirzepatide in its appraisal TA1026, published in December 2024.

Slowed gastric emptying is part of the picture too. Food leaving the stomach more slowly means fullness arrives sooner and lingers longer, so portion sizes often fall naturally over time rather than through effort alone. That said, tirzepatide is not a substitute for a reduced-calorie diet and increased activity — the licence specifies both as part of treatment. The drug changes what eating feels like; it does not change the fundamentals of energy balance.

If you want a fuller look at the mechanism, the tirzepatide drug overview covers the pharmacology in more depth.

Who are tirzepatide drugs actually licensed for in the UK?

The UK licence covers adults with a BMI of 30 or above, or adults with a BMI of 27 or above who also have at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea, or pre-diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, a detail worth raising during your consultation rather than self-assessing.

BMI alone does not determine whether treatment is appropriate. A prescriber will look at your full medical history, current medicines, and any conditions that might make tirzepatide unsuitable. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 cannot use it, and anyone who has had pancreatitis needs to discuss that history with a clinician first.

Tirzepatide is not licensed for people under 18, and it is not recommended during pregnancy, while breastfeeding, or when trying to conceive. Women using oral contraceptives should be aware that absorption of the pill may be reduced during the first four weeks of treatment and for four weeks after each dose increase, adding a barrier method during those windows is the guidance from NHS England.

For a detailed look at how private and NHS eligibility compare, the GLP-1 drugs and Mounjaro page sets it out clearly.

What does a course of tirzepatide drugs look like in practice?

Treatment begins at 2.5mg, not because that dose produces significant weight loss, but because it gives the body time to adjust to the medicine. Nausea and digestive side effects are most common when starting or after a dose increase, and the gradual schedule is designed to keep those manageable. The prescriber then reviews progress and typically increases the dose in four-week steps through 5mg, 7.5mg, 10mg, 12.5mg, and up to 15mg.

Each pen contains four weekly doses. It is injected once a week under the skin, the abdomen, thigh, or upper arm are the standard sites, rotated to avoid tissue build-up. Storage is in the fridge at 2–8°C; the NHS tirzepatide medicines page has clear guidance on storage and what to do if a dose is missed.

One habit worth building from day one: check that the pen you receive has intact packaging, a legible batch number, and a printed expiry date. It takes under a minute, and it is the simplest way to confirm the medicine came through a legitimate supply chain. Counterfeit tirzepatide pens have been seized in the UK (the MHRA's enforcement work through 2025 uncovered around 20 million doses of illegally traded weight-loss medicines worth roughly £45m) so the check matters.

Side effects to know about: nausea, diarrhoea, constipation, indigestion, and fatigue are the most commonly reported, particularly early in treatment. Severe, persistent stomach pain that spreads to the back warrants prompt medical attention, as it may signal pancreatitis. The MHRA flagged this risk in a Drug Safety Update in January 2026. Reporting unexpected reactions through the Yellow Card scheme helps the regulator monitor the medicine's ongoing safety.

How does the cost and access picture look for tirzepatide drugs in the UK?

NHS access exists but is tightly phased. From around June 2026, adults with a BMI of 35–39.9 and four or more qualifying conditions became eligible under Cohort 2 of the NHS rollout. Waiting lists vary considerably by area, and not every GP practice participates in the new prescribing contract. The NHS criteria are strict by design, the programme is being expanded carefully and in stages.

Private treatment is the route most people currently take. Pricing varies by provider and dose; since Eli Lilly raised Mounjaro's UK list price in September 2025, reported private costs have ranged roughly £149–£375 per month depending on strength and clinic. If you are weighing up your options, our guide to Mounjaro drugs explains how the medicine works and what a legitimate private prescription should include. The weight-loss drugs and Mounjaro cost page sets out what to look for and what questions to ask any provider.

At nume, clinical review sits at the centre of everything. A GPhC-registered Independent Prescriber personally reads every consultation the same day, not software, not a queue. The pharmacy is GPhC-registered (premises number 9012878, verifiable at the GPhC register), and medicines come through the licensed UK supply chain. Treatment is dispensed in plain packaging via tracked next-working-day DPD delivery once approved.

If you have questions before starting, the FAQ page covers common concerns. And if tirzepatide looks like the right direction, a free consultation with our prescribers is the natural next step.